Archer Materials Ltd

ASX:AXE

Funding & runway: Cash of $10 million with a current burn of about $2 million a quarter; management does not expect burn to change significantly for the rest of the year.

Technology progress: Management says the business has moved from early research into development — alpha biochip prototypes exist and technical derisking on qubits and sensors has advanced.

Patents ramp: 40 patents filed globally and management expects to significantly ramp filings and to double this over the coming year.

Commercialisation focus: Biochip has unlocked early commercial discussions (pharma, medtech); biochip beta prototype targeted mid-year and clinical trials targeted for 2027.

Quantum milestones: Qubit readout progress and an initial qubit demo targeted mid-year; quantum machine learning (QML) project with CSIRO is 1 year from January with early indicators mid-year and a demo by end of 2026.

New applications pipeline: QML first use-case is fraud detection (financial); other target areas discussed include healthcare imaging, logistics, sensing (TMR) for defence/aerospace, lithium sensing in blood and agtech/industrial biochip use-cases.

Commercial partnerships: Early-stage commercial discussions have begun, especially for the biochip; broader partner/licensing discussions expected to accelerate after mid-year demos and data.